期刊文献+

去势抵抗性前列腺癌的研究及治疗进展 被引量:1

Research Progress and Advances Therapy for Castration-resistant Prostate Cancer
下载PDF
导出
摘要 近年来前列腺癌发病率在我国呈上升趋势。雄激素剥夺治疗18-36个月后绝大多数患者会进展为去势抵抗性前列腺癌。随着对去势抵抗性前列腺癌的形成机制的研究以及治疗新药物的不断出现,延长了去势抵抗性前列腺癌患者的生存期,改善了生活质量。现对相关研究及治疗进展进行综述。 In recent years,the incidence of prostate cancer has been on the rise in China.After 18-36 months of androgen deprivation treatment,most patients will progress to castration-resistant prostate cancer.In recent years,with the research on the formation mechanism of castration-resistant prostate cancer and the continuous emergence of new treatment drugs,the survival period of patients with castration-resistant prostate cancer has been prolonged and the quality of life has been improved.The article reviews related research and treatment progress.
作者 刘博 张庆皎 LIU Bo;ZHANG Qing-jiao(Department of Urology,Tianjin Fourth Central Hospital,Tianjin,300140,China)
出处 《黑龙江医学》 2022年第1期125-128,共4页 Heilongjiang Medical Journal
关键词 去势抵抗性前列腺癌 机制 治疗 Castration resistant prostate cancer Mechanism Therapy
  • 相关文献

参考文献8

二级参考文献125

  • 1Yoko Matsuda,Masahito Hagio,Toshiyuki Ishiwata.Nestin:A novel angiogenesis marker and possible target for tumor angiogenesis[J].World Journal of Gastroenterology,2013,19(1):42-48. 被引量:16
  • 2于胜强,夏术阶.前列腺癌分子靶向治疗的研究进展[J].中华医学杂志,2007,87(10):718-720. 被引量:6
  • 3LAM J S,LEPPERT J T,VEMULAPALLI S N,et al.Secondary hormonal therapy for advanced prostate cancer[J].Urol,2006,175(1):27-34.
  • 4FIGG W D Ⅱ,FIGG W D.Cabazitaxel:filling one of the gaps in the treatment of prostate cancer[J].Cancer Biol Ther,2011,10(12):1233-1234.
  • 5MITA A C,DENIS L J,ROWINSKY E K,et al.Phase I and pharmacokinetic study of XRP6258 (RPR 116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors[J].Clin Cancer Res,2009,15(2):723-730.
  • 6DE-BONO J S,OUDARD S,OZGUROGLU M,et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J].Lancet,2010,376(9747):1147-1154.
  • 7SHIGETA K,MIURA Y,NAITO Y,et al.Cabazitaxel for castration-resistant prostate cancer[J].Lancet,2011,377(9760):121.
  • 8ZIVI A,MASSARD C,DE-BONO J S.Changing therapeutic paradigms in castrate-resistant prostate cancer[J].Clin Genitourin Cancer,2010,8(1):17-22.
  • 9ATTARD G,REID A H,A'HERN R,et al.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer[J].J Clin Oncol,2009,27(23):3742-3748.
  • 10DANILA D C,MORRIS M J,DE-BONO J S,et al.Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer[J].J Clin Oncol,2010,28(9):1496-1501.

共引文献108

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部